COP vs ESPR · P/E 19, rev $58.94B vs rev $332.3M
ConocoPhillips (COP) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. ESPR currently screens at market cap $816.9M.
Not investment advice. Open the COP and ESPR stock pages for the full models.
Not investment advice.